BioSpace News Archive

Doctors and researchers from across Northwell Health’s New York-based hospitals saw an “alarming number” of hospitalized coronavirus disease 2019 patients develop acute kidney injury during the height of the pandemic – rates higher than reported from China, according to new data published in Kidney International, the official journal of the International Society of Nephrology.

Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020

Announced positive preclinical data that validates the key advantages of the proprietary NeuBase peptide-nucleic acid antisense oligonucleotide (PATrOL™) platform

IntelGenx Technologies Corp. reported financial results for the first quarter ended March 31, 2020.

Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, announced its financial results for the first quarter ended March 31, 2020, and provided an update on its R&D pipeline and other corporate developments.

Company reports robust sales of COVID-19 tests as Co-Diagnostics generates net profit through middle of second quarter

Sutro Biopharma, Inc. announced the closing of its public offering of 12,650,000 shares of its common stock at a public offering price of $7.75 per share, which includes the exercise in full of the underwriters’ option to purchase 1,650,000 shares of common stock.

BioLife Solutions, Inc., a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, announced financial results for the three months ended March 31, 2020.

Biostage, Inc., a clinical-stage biotechnology company developing bioengineered organ implants based on the Company’s novel Cellspan™ technology, announced its financial results for the three months ended March 31, 2020.

Net Revenues Increased 8%; Gross Profit Up 19%, Quarter over Quarter, U.S. Sales of COVID-19 Rapid Antibody Test Kits Started in May